• Iron, KDM4D and MSC Activation Through PI3K–Akt–Foxo1

  2026-10-19

  The cited study proposes that iron deficiency suppresses quiescent mesenchymal stem-cell activation through an epigenetic-to-signaling cascade involving KDM4D, H3K9me3, PIK3R3 and PI3K–Akt–Foxo1. Its cell and mouse findings support pathway-level rescue of impaired MSC activation and bone loss, but the use of 740 Y-P is best interpreted as a downstream perturbation rather than proof that PI3K is the sole causal mediator or that any particular commercial formulation has therapeutic relevance.

• Azilsartan Medoxomil: Evidence and Mechanism Scope

  2026-10-18

  A source-grounded overview of Azilsartan Medoxomil, also identified as TAK 491, covering the supplier-documented AT1 receptor mechanism, interpretation of the reported IC50, physicochemical metadata, and the boundaries created by the absence of an identity-matched research paper.

• Cagrilintide: Identity, Mechanism and Evidence Scope

  2026-10-17

  APExBIO describes Cagrilintide (BA5265) as a long-acting acylated glucagon analog intended for obesity research, with reported activity at the amylin receptor and calcitonin receptor. The available product description supports a cautious conceptual interpretation of its proposed mechanism, but it does not provide an identity-matched study, receptor-assay results, effect sizes, sample sizes, or evidence for body-weight or food-intake outcomes.

• Flupirtine Maleate: Mechanism and Evidence Scope

  2026-10-16

  APExBIO describes Flupirtine Maleate as a non-opioid analgesic compound with muscle-relaxant properties, associating its activity with potassium-channel activation and indirect NMDA-receptor antagonism. Because no identity-matched research paper is available here, these claims should be treated as supplier-documented mechanistic context rather than evidence of efficacy, target engagement, or performance in a defined pain or neuroprotection model.

• Rucaparib, PARP Biology, and the PDAR Hypothesis

  2026-10-16

  Rucaparib is presented by APExBIO as a PARP1 inhibitor relevant to DNA damage response research, while Harper et al. describe a distinct Pol II degradation-dependent apoptotic response in a bioRxiv preprint. The available evidence supports a conceptual relationship between DNA damage signaling and regulated cell death, but it does not establish that Rucaparib causes Pol II degradation or activates PDAR.

• Recombinant Swine GM-CSF: Evidence Boundaries

  2026-10-15

  APExBIO’s listing identifies a recombinant swine GM-CSF product carrying His and Flag designations, but provides no mechanistic description, assay validation, or identity-matched research evidence. The available information therefore supports an identity-level overview only, not conclusions about receptor activity, downstream signaling, biological performance, or comparative utility.

• dCTP(100 mM): Identity, Mechanism, and Evidence

  2026-10-15

  The APExBIO listing identifies K1091 as dCTP(100 mM), consistent with a concentrated preparation of deoxycytidine triphosphate. Its molecular role in DNA synthesis can be described from established biochemical nomenclature, but the cited product information provides no matched study, formulation detail, performance data, or product-specific outcome.

• EZ Cap™ Cas9 mRNA: Evidence and Scope

  2026-10-14

  APExBIO describes EZ Cap™ Cas9 mRNA (5-moUTP) as an in vitro transcribed, Cap1- and poly(A)-modified Cas9 mRNA intended for guide-RNA-dependent genome editing. The product description supports a mechanistic rationale involving translation, RNA stability, and innate immune recognition, but no identity-matched research study or quantitative performance data are available for this SKU.

• AZD1480 and the IDO1–JAK2/STAT3 Evidence Gap

  2026-10-14

  A 2024 Journal of Immunology study links pharmacological IDO1 inhibition to tumor-intrinsic JAK2/STAT3 activation in a syngeneic mouse model. The finding provides a mechanistic rationale for studying pathway relationships, but it does not establish that AZD1480 reverses this effect, nor does it support clinical conclusions or direct comparisons with IDO1 inhibitors.

• BKT140 and the Limits of CXCR4 Oncology Evidence

  2026-10-13

  BKT140, also known as BL-8040, is presented as a CXCR4 antagonist with relevance to lymphoma biology, tumor-microenvironment research, and hematopoietic stem cell mobilization. The supplied evidence supports a biologically plausible research rationale, but it does not independently establish compound-specific clinical efficacy or safety across cancer types.

• Caspases, Autophagy, and Stress Adaptation in Cancer

  2026-10-13

  A 2025 PLOS Biology study examined whether caspase 3 and caspase 7 have non-apoptotic roles in stress adaptation in human breast cancer cells. The authors report links among effector caspases, cytoprotective autophagy, PARP1-associated DNA damage responses, and BRCA1-related vulnerability. The findings are mechanistically suggestive but remain primarily dependent on cellular models and require validation beyond the studied context.

• CCT007093, PPM1D, and Pyroptosis in AKI

  2026-10-12

  A 2024 study links WIP1/PPM1D inhibition with stronger p38-associated pyroptotic signaling in renal injury models, while leaving important questions about compound specificity, disease relevance, and clinical applicability unresolved.

• Olaparib, CLK2 and Platinum Resistance

  2026-10-12

  A 2024 ovarian cancer study links elevated CLK2 with platinum resistance through BRCA1-associated DNA damage repair, while Olaparib (AZD2281) represents a related PARP-inhibitor research context. The findings are preclinical and do not establish that Olaparib reverses CLK2-mediated resistance or improve outcomes in patients.

• Rucaparib: Evidence and Applicability Boundaries

  2026-10-11

  A source-grounded overview of Rucaparib (AG-014699) as a PARP inhibitor, distinguishing supplier-reported mechanisms from the limited evidence supplied in a non-peer-reviewed Pol II degradation preprint.

• Imatinib in Erythroleukemia Signaling Research

  2026-10-10

  A source-grounded overview of Imatinib (STI571) in kinase signaling research, emphasizing a 2026 Cellular Signalling study of roxadustat, HIF signaling, GATA1-dependent erythroid differentiation, reported combination effects, evidence strength, and the limits of translating cell-line findings to clinical cancer biology.

555 records 1/37 page Next 12345 下5页 Last page